Shuang G Zhao

List of Publications by Year in Descending Order

51 papers	3,741 citations	27 h-index	54 g-index
54 ext. papers	4,988 ext. citations	10.5 avg, IF	4.55 L-index

#	Paper	IF	Citations
51	SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples.. *Clinical Epigenetics*, **2022**, 14, 37	7.7	0
50	Reply to M. K. Bos et al. *Journal of Clinical Oncology*, **2021**, JCO2102238	2.2	
49	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 544-552	13.4	17
48	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. *European Urology*, **2021**, 79, 717-721	10.2	4
47	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. *European Urology*, **2021**, 79, 374-383	10.2	28
46	ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. *Molecular Cancer Therapeutics*, **2021**, 20, 2129-2139	6.1	2
45	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. *Npj Genomic Medicine*, **2021**, 6, 76	6.2	2
44	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. *Journal of Clinical Oncology*, **2021**, 39, 2926-2937	2.2	10
43	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. *JAMA Oncology*, **2021**, 7, 1644-1652	13.4	2
42	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5
41	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 646-653	6.2	6
40	A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences. *International Journal of Radiation Oncology Biology Physics*, **2020**, 108, 686-696	4	5
39	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. *Cancer*, **2020**, 126, 717-724	6.4	36
38	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 316-323	6.2	3
37	SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. *Scientific Reports*, **2020**, 10, 15890	4.9	1
36	The DNA methylation landscape of advanced prostate cancer. *Nature Genetics*, **2020**, 52, 778-789	36.3	71
35	Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. *European Urology*, **2020**,	10.2	2

#	Citation	IF	Citations
34	Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. *Nature Communications*, **2020**, 11, 3811	17.4	34
33	Autoantibody Landscape in Patients with Advanced Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 6204-6214	12.9	4
32	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. *Neuro-Oncology*, **2019**, 21, 1141-1149	11	6
31	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. *Clinical Cancer Research*, **2019**, 25, 4290-4299	12.9	15
30	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2019**, 22, 531-538	6.2	32
29	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. *Cancer*, **2019**, 125, 3338-3346	6.4	10
28	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. *Clinical Cancer Research*, **2019**, 25, 5608-5622	12.9	10
27	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. *Clinical Cancer Research*, **2019**, 25, 6721-6730	12.9	35
26	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. *European Urology Oncology*, **2019**, 2, 405-412	6.7	8
25	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. *Clinical Cancer Research*, **2019**, 25, 2450-2457	12.9	23
24	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. *Journal of the National Cancer Institute*, **2019**, 111, 301-310	9.7	99
23	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell*, **2018**, 174, 758-769.e9	56.2	234
22	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. *European Urology Oncology*, **2018**, 1, 276-282	6.7	4
21	PARP-1 regulates DNA repair factor availability. *EMBO Molecular Medicine*, **2018**, 10,	12	35
20	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. *Clinical Cancer Research*, **2018**, 24, 3908-3916	12.9	10
19	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. *European Urology*, **2018**, 74, 444-452	15.2	35
18	Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. *BJU International*, **2017**, 120, 351-357	5.6	5
17	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. *JAMA Oncology*, **2017**, 3, 1663-1672	13.4	138

16	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. *Cancer Research*, **2017**, 77, 1021-1034	10.1	74
15	Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. *Cancer Research*, **2017**, 77, 960-970	10.1	50
14	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. *Npj Breast Cancer*, **2017**, 3, 29	7.8	27
13	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. *Journal of Urology*, **2017**, 197, 662-668	2.5	59
12	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. *Lancet Oncology, The*, **2016**, 17, 1612-1620	21.7	124
11	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. *Nature Communications*, **2016**, 7, 12791	17.4	152
10	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. *JAMA Oncology*, **2016**, 2, 471-80	13.4	38
9	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 1777-86	12.9	30
8	Independent surgical validation of the new prostate cancer grade-grouping system. *BJU International*, **2016**, 118, 763-769	5.6	39
7	Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. *Head and Neck*, **2016**, 38 Suppl 1, E1086-96	4.2	28
6	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 5864-5875	12.9	64
5	The landscape of long noncoding RNAs in the human transcriptome. *Nature Genetics*, **2015**, 47, 199-208	36.3	1789
4	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. *Cancer Cell*, **2015**, 28, 97-113	24.3	116
3	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. *Radiotherapy and Oncology*, **2015**, 116, 179-84	5.3	46
2	Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. *Clinical Cancer Research*, **2015**, 21, 3667-77	12.9	86
1	A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer. *Translational Oncology*, **2014**, 7, 429-429	4.9	30